rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    IBRX
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      IBRX CEO Reveals Fresh Anktiva Data After Bladder Cancer Trial Win — Says FDA Filing Is Just Weeks Away
      Nov 17Yahoo FinanceIBRX
      ImmunityBio at UBS Global Biopharma Conference 2026: broadening ANKTIVA
      Nov 16Investing.comIBRXUBS
      IBRX Stock In Focus As Institutional Investor Boosts Stake By Over 15% In Q3 — All Eyes On ImmunityBio’s London Conferences Next Week
      Nov 13Yahoo FinanceIBRX
      ImmunityBio (IBRX) is Declining For 4 Days Now. What’s Triggering the Selloff?
      Nov 13Yahoo FinanceIBRX
      ImmunityBio to Participate in UK Investor Conferences During London Life Sciences Week 2026
      Nov 11Yahoo FinanceIBRX
      IBRX Q3 Earnings Miss, Anktiva Sales Decline Q/Q, Stock Down 18%

      ImmunityBio's revenues jump 53% on Anktiva adoption, but a wider-than-expected loss, sequential sales decline and rising expenses weigh on shares.

      Nov 10Yahoo FinanceIBRX
      ImmunityBio shares slump 19% as revenue misses and going-concern warning hits sentiment

      ImmunityBio Inc (NASDAQ:IBRX) shares fell 19% to US$6.97 after the biotechnology company reported a third-quarter revenue shortfall and a sharply wider net loss. The US biopharmaceutical company generated revenue of US$48.84 million in the three months to September 2026, up 52% year on year but...

      Nov 9Yahoo FinanceIBRX
      Immunitybio Inc earnings missed by $0.10, revenue fell short of estimates
      Nov 9Investing.comIBRX
      Why Is ImmunityBio Stock Trading Lower On Monday? - ImmunityBio (NASDAQ:IBRX)
      Nov 9BenzingaIBRX
      IBRX Stock Crashes To Near 9-Month Lows On Q3 Earnings Miss – Retail Says No Way To Escape Further Dilution
      Nov 9Yahoo FinanceIBRX
      Why is Immunitybio stock sliding today?
      Nov 9Investing.comIBRX
      ImmunityBio (IBRX) Reports Q3 Loss, Misses Revenue Estimates
      Nov 9Yahoo FinanceIBRX
      ImmunityBio reports 92% revenue growth, FDA label expansion
      Nov 9Investing.comIBRX
      ImmunityBio: Q3 Earnings Snapshot
      Nov 9Yahoo FinanceIBRX
      ImmunityBio Reports Label Expansion and Additional Global Approval with Q3 2026 Net Product Revenue of $48.7 Million, Up 53% Year-Over-Year and First Nine Months U.S. Revenue Up 92% to $143.6 Million
      Nov 9Yahoo FinanceIBRX
      ImmunityBio and Rafa Announce Israeli Ministry of Health Approval of ANKTIVA® Plus BCG for BCG-Unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
      Nov 9Yahoo FinanceIBRX
      ImmunityBio’s Anktiva meets trial goal for bladder cancer
      Nov 9Investing.comIBRX
      ImmunityBio Announces ANKTIVA® Plus BCG Meets Primary Endpoint in BCG-Naïve Non-Muscle Invasive Bladder Cancer Randomized QUILT-2.005 Trial
      Nov 9Yahoo FinanceIBRX
      Does ImmunityBio (IBRX) Look Fully Priced After A 310% Jump?
      Nov 4Yahoo FinanceIBRX
      How Investors May Respond To ImmunityBio (IBRX) Europe Launch And Trial Progress
      Nov 4Yahoo FinanceIBRX
      ImmunityBio (IBRX) Could Be 42% Below Fair Value After Trial Database Lock
      Nov 4Yahoo FinanceIBRX
      Immunitybio earnings on deck: Can ANKTIVA approval fuel growth?
      Nov 4Investing.comIBRX
      ImmunityBio Treats First Patients In Europe With Anktiva Plus BCG – Retail Calls It A ‘Great Opening Act’ For Q3 Earnings
      Nov 4Yahoo FinanceIBRX
      ImmunityBio Announces First Patients in Europe Treated with ANKTIVA® Plus BCG for BCG-unresponsive Non-Muscle Invasive Bladder Cancer with Carcinoma in Situ
      Nov 4Yahoo FinanceIBRX
      Jim Cramer Calls Celsius 'A Second-Rate Monster,' Says Stick With the Original
      Oct 27BenzingaCELHIBRX
      IBRX Stock Rises Overnight: Jim Cramer Backs ImmunityBio As A ‘Very Good Spec’ Amid Biotech Takeover Wave
      Oct 27Yahoo FinanceIBRX
      ImmunityBio Locks Anktiva Trial Database, Eyes November Results As FDA Filing Nears
      Oct 21Yahoo FinanceIBRX
      ImmunityBio completes database lock for bladder cancer trial
      Oct 21Investing.comIBRX
      ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
      Oct 21Yahoo FinanceIBRX
      ANKTIVA Label Expansion Could Change The Case For ImmunityBio Stock
      Oct 19Yahoo FinanceIBRX
      ImmunityBio Study Shows Long-Term Success for Bladder Cancer Treatment - ImmunityBio (NASDAQ:IBRX)

      New data show ImmunityBio's ANKTIVA combined with BCG provides durable responses and high survival rates in unresponsive bladder cancer.

      Oct 19BenzingaIBRX
      ImmunityBio: Not Executing At The Level That The Market Is Pricing In (NASDAQ:IBRX)

      ImmunityBio, Inc. expands Anktiva's label in bladder cancer, fueling robust sales growth but facing skepticism over pipeline durability. Learn more about IBRX stock here.

      Oct 19Seeking AlphaIBRX
      ImmunityBio reports long-term bladder cancer treatment data
      Oct 16Investing.comIBRX
      ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
      Oct 16Yahoo FinanceIBRX
      ImmunityBio: Jury May Still Be Out On Anktiva Despite Latest NMIBC Win (NASDAQ:IBRX)

      ImmunityBio has secured early FDA label expansion for Anktiva in BCG-unresponsive NMIBC. Check out why IBRX stock is a hold.

      Oct 16Seeking AlphaIBRX
      FDA Expands ImmunityBio's Anktiva Label in Bladder Cancer
      Oct 15Yahoo FinanceIBRX
      H.C. Wainwright reiterates Immunitybio stock rating on FDA approval expansion
      Oct 15Investing.comIBRX
      ImmunityBio Stock Climbs Thursday: What's Going On? - ImmunityBio (NASDAQ:IBRX)

      ImmunityBio shares are trading higher Thursday after the FDA approved expansion for its bladder cancer therapy ANKTIVA.

      Oct 15BenzingaIBRX
      ImmunityBio’s bladder cancer drug, Anktiva lands US label expansion
      Oct 15Yahoo FinanceIBRX
      FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
      Oct 14Yahoo FinanceIBRX
      Why Is ImmunityBio Stock Gaining Wednesday? - ImmunityBio (NASDAQ:IBRX)

      ImmunityBio (IBRX) stock jumps over 5% following FDA expanded approval for Anktiva in NMIBC bladder cancer treatment. Get details.

      Oct 14BenzingaIBRX
      IBRX Stock Rallies After FDA Clears Broader Anktiva Use In Bladder Cancer Months Ahead Of Deadline
      Oct 14Yahoo FinanceIBRX
      10 Health Care Stocks Whale Activity In Today’s Session - ImmunityBio (NASDAQ:IBRX), Boston Scientific (N

      This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner. Traders will

      Oct 9BenzingaIBRX
      ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
      Oct 8Yahoo FinanceIBRXPIPR
      ImmunityBio (IBRX) Could Be 33% Undervalued Following Its Ottawa Symposium Update
      Oct 8Yahoo FinanceIBRX
      ImmunityBio director Barry Simon sells $268,760 in stock
      Oct 6Investing.comIBRX
      ImmunityBio director Cheryl Cohen sells $851,088 in shares
      Oct 6Investing.comIBRX
      ImmunityBio Stock Jumps: What's Going On? - ImmunityBio (NASDAQ:IBRX)

      ImmunityBio Inc. (NASDAQ: IBRX) shares are soaring Friday, extending a steadily rising pattern that's played out over the past several months.

      Oct 2BenzingaIBRX
      A $5.8B Cancer Market Opportunity Is Emerging — Why GA-Courtenay Favors ImmunityBio (IBRX)
      Sep 30Yahoo FinanceIBRX
      ImmunityBio (IBRX) Meeting With Turkish President Fuels Expansion Hopes, Shares Climb 10%
      Sep 23Yahoo FinanceIBRX

      This is the newest page. Registered accounts read further back.